Search

Your search keyword '"Papot, Emmanuelle"' showing total 30 results
Start Over Author "Papot, Emmanuelle"
30 results on '"Papot, Emmanuelle"'

1. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

Author

Papot, Emmanuelle, Tovar-Sanchez, Tamara, Woods, Joana, Thaurignac, Guillaume, Eriobu, Nnakelu, Borok, Margaret, Kaplan, Richard, Avihingsanon, Anchalee, Azwa, Iskandar, Grinsztejng, Beatriz, Kumarasamy, Nagalingeswaran, Sokhela, Simiso, Mpoudi-Etame, Mireille, Arriaga, Maria, Jacoby, Simone, Matthews, Gail V., Losso, Marcelo H., Khoo, Saye, Calmy, Alexandra, Kouanfack, Charles, Ayouba, Ahidjo, Petoumenos, Kathy, Venter, W.D.Francois, Delaporte, Eric, and Polizzotto, Mark N.

Published
2024
Full Text
View/download PDF

3. SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa

Author

Papot, Emmanuelle, Tovar-Sanchez, Tamara, Woods, Joana, Thaurignac, Guillaume, Eriobu, Nnakelu, Borok, Margaret, Kaplan, Richard, Avihingsanon, Anchalee, Azwa, Iskandar, Grinsztejng, Beatriz, Kumarasamy, Nagalingeswaran, Sokhela, Simiso, Mpoudi-Etame, Mireille, Arriaga, Maria, Jacoby, Simone, Matthews, Gail V., Losso, Marcelo H., Khoo, Saye, Calmy, Alexandra, Kouanfack, Charles, Ayouba, Ahidjo, Petoumenos, Kathy, Venter, W.D. Francois, Delaporte, Eric, and Polizzotto, Mark N.

Published
2025
Full Text
View/download PDF

4. Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia

Author

Dharan, Nila J., primary, Sasson, Sarah C., additional, Ahlenstiel, Golo, additional, Andersen, Christopher R., additional, Bloch, Mark, additional, Buckland, Griselda, additional, Hamad, Nada, additional, Han, Win Min, additional, Kelleher, Anthony D., additional, Long, Georgina V., additional, Matthews, Gail V., additional, Mina, Michael M., additional, Papot, Emmanuelle, additional, Petoumenos, Kathy, additional, Swaminathan, Sanjay, additional, Withers, Barbara, additional, Yun, James, additional, and Polizzotto, Mark N., additional

Published
2023
Full Text
View/download PDF

5. Metabolic syndrome and endocrine status in HIV-infected transwomen

Author

Pommier, Jean-David, Laouénan, Cedric, Michard, Florence, Papot, Emmanuelle, Urios, Paul, Boutten, Anne, Peytavin, Gilles, Ghander, Cecile, Lariven, Sylvie, Castanedo, Gerald, Moho, David, Landman, Rolland, Phung, Bao, Perez, Estela, Julia, Zelie, Descamps, Diane, Roland-Nicaise, Pascale, Le Gac, Sylvie, Yazdanpanah, Yazdan, Guibourdenche, Jean, and Yeni, Patrick

Published
2019
Full Text
View/download PDF

6. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Author

Jordans, Carlijn C.E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M.N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Sǎndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., Rokx, Casper, Medical Microbiology & Infectious Diseases, Jordans, C, Vasylyev, M, Rae, C, Jakobsen, M, Vassilenko, A, Dauby, N, Grevsen, A, Jakobsen, S, Raahauge, A, Champenois, K, Papot, E, Malin, J, Boender, T, Behrens, G, Gruell, H, Neumann, A, Spinner, C, Valbert, F, Akinosoglou, K, Kostaki, E, Nozza, S, Giacomelli, A, Lapadula, G, Mazzitelli, M, Torti, C, Matulionyte, R, Matulyte, E, Van Welzen, B, Hensley, K, Thompson, M, Ankiersztejn-Bartczak, M, Skrzat-Klapaczyńska, A, Săndulescu, O, Streinu-Cercel, A, Miron, V, Pokrovskaya, A, Hachfeld, A, Dorokhina, A, Sukach, M, Lord, E, Sullivan, A, and Rokx, C

Subjects
Europe, SDG 3 - Good Health and Well-being, Epidemiology, HIV, indicator conditions, AIDS-defining condition, Virology, Public Health, Environmental and Occupational Health, Medizin, guidelines, Wirtschaftswissenschaften, 610 Medizin und Gesundheit
Abstract

Background Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90–90–90 goals and medical specialty). Results Of 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38–68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90–90–90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines. Conclusion Fewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.

Published
2022

7. Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia.

Author

Dharan, Nila J., Sasson, Sarah C., Ahlenstiel, Golo, Andersen, Christopher R., Bloch, Mark, Buckland, Griselda, Hamad, Nada, Han, Win Min, Kelleher, Anthony D., Long, Georgina V., Matthews, Gail V., Mina, Michael M., Papot, Emmanuelle, Petoumenos, Kathy, Swaminathan, Sanjay, Withers, Barbara, Yun, James, and Polizzotto, Mark N.

Subjects
IMMUNOCOMPROMISED patients, SARS-CoV-2 Delta variant, PATHOLOGICAL laboratories, COVID-19, COVID-19 pandemic
Abstract

People with immunocompromising conditions are at increased risk of SARS-CoV-2 infection and mortality, however early in the pandemic it was challenging to collate data on this heterogenous population. We conducted a registry study of immunocompromised individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection from March–October 2020 in Sydney, Australia to understand clinical and laboratory outcomes in this population prior to the emergence of the Delta variant. 27 participants were enrolled into the study including people with a haematologic oncologic conditions (n = 12), secondary immunosuppression (N = 8) and those with primary or acquired immunodeficiency (i.e. HIV; N = 7). All participants had symptomatic COVID-19 with the most common features being cough (64%), fever (52%) and headache (40%). Five patients demonstrated delayed SARS-CoV-2 clearance lasting three weeks to three months. The mortality rate in this study was 7% compared to 1.3% in the state of New South Wales Australia during the same period. This study provides data from the first eight months of the pandemic on COVID-19 outcomes in at-risk patient groups. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

8. Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression

Author

Supervie, V, Assoumou, L, Breban, R, Lert, F, Costagliola, D, Pialoux, G, Landman, R, Girard, P. M, Slama, L, Cabié, André, Abel, Sylvie, Hochedez, Patrick, Pierre-François, Sandrine, Rozé, Benoît, Simon, Anne, Lupin, Catherine, Katlama, Christine, Valentin, Marc Antoine, Autran, Brigitte, Samri, Assia, Lambert, Sidonie, Marcelin, Anne Geneviève, Landman, Roland, Joly, Véronique, Julia, Zélie, Harent, Stanislas, Papot, Emmanuelle, Phung, Bao-Chau, Peytavin, Gilles, Minh, Patrick Lê, Rami, Agathe, Diemer, Myriam, Parrinello, Maguy, Cahitte, Isabelle, Zeng, Feng, Mortier, Emmanuel, Pialoux, Gilles, L’Yavanc, Thomas, Le Loup, Guillaume, Bonnard, Philippe, Lebrette, Marie Gisèle, Chas, Julie, Berrebi, Valérie, Velazquez, Nadège, Adda, Anne, Duvivier, Claudine, Touam, Fatima, Lortholary, Olivier, Shoai-Tehrani, Michka, Rouzaud, Claire, Denes, Eric, Ducroux-Roubertou, Sophie, Durox, Hélène, Genet, Claire, Rogez, Jean-Philippe, Rogez, Sylvie, Pascual, Jose, Weiss, Laurence, Pavie, Juliette, Bourzam, Erila, Aumaître, Hugues, Ferreyra, Milagros, Saada, Matthieu, Malet, Martine, Palacios, Christia, Honore, Patricia, Zamord, Irene, Berthe, Huguette, Landowski, Stéphanie, de Truchis, Pierre, Perre, Philippe, Girard, Pierre-Marie, Valin, Nadia, Campa, Pauline, Lefebvre, Bénédicte, Meynard, Jean-Luc, Pauchard, Michèle, and Surgers, Laure

Published
2017
Full Text
View/download PDF

10. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D 2 EFT

Author

Papot, Emmanuelle, primary, Jacoby, Simone, additional, Arlinda, Dona, additional, Avihingsanon, Anchalee, additional, Azwa, Iskandar, additional, Borok, Margaret, additional, Brown, Dannae, additional, Cissé, Mohamed, additional, Dao, Sounkalo, additional, Eriobu, Nnakelu, additional, Kaplan, Richard, additional, Karyana, Muhammad, additional, Kumarasamy, Nagalingeswaran, additional, Lee, Johnnie, additional, Losso, Marcelo H., additional, Matthews, Gail V., additional, Perelis, Leonardo, additional, Perez-Casas, Carmen, additional, Ruxrungtham, Kiat, additional, Watkins, Melynda, additional, Lane, H. Clifford, additional, Kelleher, Anthony, additional, Law, Matthew, additional, and Polizzotto, Mark N., additional

Published
2022
Full Text
View/download PDF

11. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT

Author

Papot, Emmanuelle ; https://orcid.org/0000-0003-2782-0263, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cisse, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Losso, Marcelo H, Matthews, Gail V ; https://orcid.org/0000-0002-1048-6396, Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham,, Kiat, Watkins, Melynda, Lane, H Clifford, Kelleher, Anthony ; https://orcid.org/0000-0002-0009-3337, Law, Matthew ; https://orcid.org/0000-0002-3540-8837, Polizzotto, Mark, Papot, Emmanuelle ; https://orcid.org/0000-0003-2782-0263, Jacoby, Simone ; https://orcid.org/0000-0001-6391-9717, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cisse, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Losso, Marcelo H, Matthews, Gail V ; https://orcid.org/0000-0002-1048-6396, Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham,, Kiat, Watkins, Melynda, Lane, H Clifford, Kelleher, Anthony ; https://orcid.org/0000-0002-0009-3337, Law, Matthew ; https://orcid.org/0000-0002-3540-8837, and Polizzotto, Mark

Abstract

A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D2EFT investigators to consider the impact of the roll-out of TLD on the D2EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial

Published
2022

12. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Author

Jordans, Carlijn C. E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M. N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczynska, Agata, Sandulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., Rokx, Casper, Jordans, Carlijn C. E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M. N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczynska, Agata, Sandulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., and Rokx, Casper

Abstract

Background: Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim: To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods: Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90- 90-90 goals and medical specialty). Results: Of 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern ( 53%) than western (42%) European countries and in countries yet to achieve the 90-90- 90 goals ( 52%) compared to those that had ( 38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines. Conclusion: Fewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.

Published
2022

13. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations:a systematic guideline review

Author

Jordans, Carlijn C.E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M.N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Sǎndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., Rokx, Casper, Jordans, Carlijn C.E., Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, T. Sonia, Behrens, Georg M.N., Gruell, Henning, Neumann, Anja, Spinner, Christoph D., Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G., Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J., Hensley, Kathryn S., Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Sǎndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., and Rokx, Casper

Abstract

Background: Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim: To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods: Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty). Results: Of 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines. Conclusion: Fewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.

Published
2022

14. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Author

Jordans, Carlijn, Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, Sonia, Behrens, Georg M.N, Gruell, Henning, Neumann, Anja, Spinner, Christoph D, Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia, Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend, Hensley, Kathryn, Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Săndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., Rokx, Casper, Jordans, Carlijn, Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J., Boender, Sonia, Behrens, Georg M.N, Gruell, Henning, Neumann, Anja, Spinner, Christoph D, Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia, Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend, Hensley, Kathryn, Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Săndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K., and Rokx, Casper

Abstract

Background Adequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing. Aim To evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries. Methods Between 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90–90–90 goals and medical specialty). Results Of 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38–68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90–90–90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines. Conclusion Fewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

15. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review

Author

MS Interne Geneeskunde, Jordans, Carlijn C E, Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J, Boender, T Sonia, Behrens, Georg M N, Gruell, Henning, Neumann, Anja, Spinner, Christoph D, Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G, Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J, Hensley, Kathryn S, Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Săndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K, Rokx, Casper, Guidelines Review Group for the projects: Optimising testing and linkage to care for HIV across Europe (OptTEST by HiE) and the Joint Action on integrating prevention, testing and linkage to care strategies across HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE), MS Interne Geneeskunde, Jordans, Carlijn C E, Vasylyev, Marta, Rae, Caroline, Jakobsen, Marie Louise, Vassilenko, Anna, Dauby, Nicolas, Grevsen, Anne Louise, Jakobsen, Stine Finne, Raahauge, Anne, Champenois, Karen, Papot, Emmanuelle, Malin, Jakob J, Boender, T Sonia, Behrens, Georg M N, Gruell, Henning, Neumann, Anja, Spinner, Christoph D, Valbert, Frederik, Akinosoglou, Karolina, Kostaki, Evangelia G, Nozza, Silvia, Giacomelli, Andrea, Lapadula, Giuseppe, Mazzitelli, Maria, Torti, Carlo, Matulionyte, Raimonda, Matulyte, Elzbieta, Van Welzen, Berend J, Hensley, Kathryn S, Thompson, Magdalena, Ankiersztejn-Bartczak, Magdalena, Skrzat-Klapaczyńska, Agata, Săndulescu, Oana, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Miron, Viktor Daniel, Pokrovskaya, Anastasia, Hachfeld, Anna, Dorokhina, Antonina, Sukach, Maryna, Lord, Emily, Sullivan, Ann K, Rokx, Casper, and Guidelines Review Group for the projects: Optimising testing and linkage to care for HIV across Europe (OptTEST by HiE) and the Joint Action on integrating prevention, testing and linkage to care strategies across HIV, viral hepatitis, TB and STIs in Europe (INTEGRATE)

Published
2022

17. Can we talk about price with patients when choosing antiretroviral therapy? A survey with people living with HIV and prescribers in France

Author

Papot, Emmanuelle, Kalampalikis, Nikos, Doumergue, Marjolaine, Pilorgé, Fabrice, Quatremère, Guillemette, Yazdanpanah, Yazdan, Préau, Marie, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe de Recherche en Psychologie Sociale (GRePS), Université Lumière - Lyon 2 (UL2), AIDES [Pantin, France], Radiations : Défense, Santé, Environnement [Lyon] ( Inserm U1296 / UL2), Université Lumière - Lyon 2 (UL2)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Psychologie, ANRS-GOTA study group: Philippe Arnaud, Claire Auger, Franck Barbier, Gaele Bruneaux, Katia Bourdic, Elisabeth Bouvet, Agnès Certain, Charlotte Charpentier, Marjolaine Doumergue, Véronique Doré, Cécile Goujard, Sophia Guessous, Anne-Claire Haye, Nikos Kalampalikis, Roland Landman, Sylvie LeGac, Françoise Louni, David Michels, Philippe Morlat, Dorothée Obach, Emmanuelle Papot, Gilles Peytavin, Fabrice Pilorgé, Laurence Pochat, Marie Préau, Guillemette Quatremère, Daniela Rojas Castro, Yazdan Yazdanpanah, Patrick Yéni, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Radiations : Défense, Santé, Environnement [Lyon] (Inserm UA8), Institut National de la Santé et de la Recherche Médicale (INSERM), and Malbec, Odile

Subjects
[SDV] Life Sciences [q-bio], Cross-Sectional Studies, Anti-Retroviral Agents, [SDV]Life Sciences [q-bio], Surveys and Questionnaires, public health, HIV/AIDS, HIV & AIDS, Humans, epidemiology, HIV Infections, Focus Groups
Abstract

International audience; Objective The aim of this study was to evaluate people living with HIV (PLWH) and HIV specialist prescribers' perception of discussing antiretroviral therapy (ART) price in PLWH's care and the acceptability of choosing or switching to various types of less expensive ARTs. Design Cross-sectional surveys (one in a convenience sample of PLWH and one in a voluntary response sample of HIV specialist prescribers). Setting and participants The surveys were conducted among PLHW attending an HIV clinic in the North of Paris (cohort of 4922 PLWH in 2016), and HIV specialists working in French HIV clinics (210 across 12 districts/28), between January and June 2016. Method Self-administered questionnaires were constructed using data collected during focus groups with PLWH and prescribers. Pretests were carried out to select the questions and items. Descriptive analyses of the 129 complete questionnaires of PLWH and 79 of prescribers are presented. Results Among PLWH, 128/129 were on ART and 54% (69/128) gave a fair estimation of the price of their current regimen. Among prescribers, 24% (19/79) thought that their patients knew this price. Taking into account the price of ART was not perceived as a negative step in the history of French response to HIV epidemic for 53% (68/129) of PLWH and 82% (65/79) of prescribers. Seventy-seven PLWH (60%) would agree to switch to less expensive antiretroviral regimens (as effective and with similar adverse events) if pills were bigger; 42 (33%) if there were more daily doses, and 37 (29%) if there were more pills per dose; prescribers were more circumspect. Conclusion A high proportion of PLWH gave a fair estimate of their ART price and this seemed unexpected by HIV specialists. Consideration of drug prices when choosing ART was perceived as conceivable by PLWH and prescribers if effectiveness and tolerance were also considered.

Published
2021
Full Text
View/download PDF

19. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.

Author

Papot, Emmanuelle, Jacoby, Simone, Arlinda, Dona, Avihingsanon, Anchalee, Azwa, Iskandar, Borok, Margaret, Brown, Dannae, Cissé, Mohamed, Dao, Sounkalo, Eriobu, Nnakelu, Kaplan, Richard, Karyana, Muhammad, Kumarasamy, Nagalingeswaran, Lee, Johnnie, Losso, Marcelo H., Matthews, Gail V., Perelis, Leonardo, Perez-Casas, Carmen, Ruxrungtham, Kiat, and Watkins, Melynda

Subjects
RITONAVIR, NON-nucleoside reverse transcriptase inhibitors, REVERSE transcriptase inhibitors, CLINICAL trials, EXPERIMENTAL design, STATISTICAL bias
Abstract

A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D2EFT investigators to consider the impact of the roll-out of TLD on the D2EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The D2EFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Incidence of and risk factors for medical care interruption in people living with HIV in recent years

Author

Fournier, Anna Lucie, Yazdanpanah, Yazdan, Verdon, Renaud, Lariven, Sylvie, Mackoumbou-Nkouka, Claude, Phung, Bao-Chau, Papot, Emmanuelle, Parienti, Jean-Jacques, Landman, Roland, Champenois, Karen, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Unité de Maladies Infectieuses et Tropicales [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Institut de médecine et d'épidémiologie appliquée [AP-HP Hôpital Bichat-Claude Bernard] (IMEA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), and Mzembaba, Sandy

Subjects
RNA viruses, Male, Medical Doctors, Health Care Providers, HIV Infections, Pathology and Laboratory Medicine, Geographical locations, Immunodeficiency Viruses, Risk Factors, Public and Occupational Health, Medical Personnel, ComputingMilieux_MISCELLANEOUS, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Incidence, HIV diagnosis and management, Viral Load, Middle Aged, Vaccination and Immunization, Europe, Professions, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Anti-Retroviral Agents, Medical Microbiology, Viral Pathogens, Viruses, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Medicine, Female, France, Pathogens, Research Article, Adult, Science, Immunology, Antiretroviral Therapy, Microbiology, Antiviral Therapy, Physicians, Virology, Retroviruses, Humans, European Union, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, Microbial Pathogens, Primary Care, Africa South of the Sahara, Medicine and health sciences, Lentivirus, Organisms, Biology and Life Sciences, HIV, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Diagnostic medicine, CD4 Lymphocyte Count, Health Care, People and Places, HIV-1, Population Groupings, Preventive Medicine, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Delivery of Health Care, Viral Transmission and Infection, Follow-Up Studies
Abstract

ObjectivesWith HIV treatment as a prevention strategy, retention in care remains a key for sustained viral suppression. We sought to identify HIV-infected patients at risk for medical care interruption (MCI) in a high-income country.MethodsThe HIV-infected patients enrolled had to attend the clinic at least twice between January 2010 and October 2014 and were followed up until May 2016. MCI was defined as patients not seeking care in or outside the clinic for at least 18 months, regardless of whether they returned to care after the interruption. The association between MCI and sociodemographic, clinical, and immuno-virological characteristics at HIV diagnosis and during follow-up was assessed using Cox models.ResultsThe incidence rate of MCI was 2.5 per 100 persons-years (95% confidence interval [CI] = 2.3-2.7). MCI was more likely in patients who accessed care >6 months after diagnosis (hazard ratio [HR] = 1.30, 95% CI = 1.10-1.54 vs. ≤6 months) or did not report a primary care physician (HR = 2.40; 95% CI = 2.03-2.84). MCI was less likely in patients born in sub-Saharan Africa (HR = 0.75, 95% CI = 0.62-0.91 vs. born in France). During follow-up, the risk of MCI increased when the last CD4 count was ≤350 (HR = 2.85, 95% CI = 2.02-4.04 vs. >500 cells/mm3) and when the patient was not on antiretroviral therapy (HR = 3.67, 95% CI = 2.90-4.66).ConclusionsThe incidence of MCI is low in this hospital that serves a large proportion of migrants. Low or no recorded CD4 counts for a medical visit could alert of a higher risk of MCI, even more in patients who accessed HIV care late or did not report a primary care physician.

Published
2019
Full Text
View/download PDF

23. Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris

Author

Couffignal, Camille, primary, Papot, Emmanuelle, additional, Etienne, Aurélie, additional, Legac, Sylvie, additional, Laouénan, Cédric, additional, Beres, Danièle, additional, Blum, Laurent, additional, Khuong-Josses, Marie-Aude, additional, Lepretre, Annie, additional, Papazian, Patrick, additional, Yazdanpanah, Yazdan, additional, and Bouvet, Elisabeth, additional

Published
2019
Full Text
View/download PDF

24. Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris.

Author

Couffignal, Camille, Papot, Emmanuelle, Etienne, Aurélie, Legac, Sylvie, Laouénan, Cédric, Beres, Danièle, Blum, Laurent, Khuong-Josses, Marie-Aude, Lepretre, Annie, Papazian, Patrick, Yazdanpanah, Yazdan, and Bouvet, Elisabeth

Subjects
*DIAGNOSIS of HIV infections, *HIV infection transmission, *BEHAVIOR modification, *COUNSELING, *DRUGS, *FEAR, *HIV infections, *PSYCHOLOGY of HIV-positive persons, *MEDICAL appointments, *MEDICAL cooperation, *PATIENT compliance, *PHYSICIAN-patient relations, *QUESTIONNAIRES, *RESEARCH, *SELF-evaluation, *HUMAN sexuality, *SURVEYS, *ANTIRETROVIRAL agents, *CROSS-sectional method, *HIV seroconversion, *HEALTH literacy, *MEN who have sex with men
Abstract

We evaluated awareness of treatment as prevention (TasP) among adults people living with HIV (PLHIV) in five infectious disease departments in Paris, then how they perceived its impact on their sexual well-being. This cross-sectional multicenter survey was conducted in 2014 during scheduled clinical appointments using a self-administered questionnaire. We analyzed 520 questionnaires (42% women, 54% men of whom 57% were MSM [men who have sex with men]). 75% of women were born abroad, most commonly in sub-Saharan Africa, whereas 64% of men were French-born. The mean time since HIV diagnosis was 12.8 ± 7.8 years. Eighty-seven percent [84−90%]95% reported being aware of the impact of ART on HIV transmission, 94% MSM, 86% women, 83% heterosexual men. PLHIV reported that they gained awareness of TasP through medical doctors (86%). The fear of transmission was perceived as alleviated for 73% [69%;78%]95%, more often among MSM; the sexual life was reported to be improved for 28% [24%;33%]95%; and ART adherence to be improved for 45% [40%;50%]95%, more often among women. The awareness of TasP was relatively high, but it seems important to understand the features of male and female populations of PLHIV to adapt counseling during follow-up appointments, as women's answers differed in various regards. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

26. HIV-1 Pol Gene Polymorphism and Antiretroviral Resistance Mutations in Treatment-Naive Adult Patients in French Guiana Between 2006 and 2012

Author

Darcissac, Edith, primary, Nacher, Mathieu, additional, Adriouch, Leila, additional, Berlioz-Arthaud, Alain, additional, Boukhari, Rachida, additional, Couppié, Pierre, additional, Djossou, Felix, additional, Donato, Damien, additional, El Guedj, Myriam, additional, Lavergne, Anne, additional, Papot, Emmanuelle, additional, Pouliquen, Jean-François, additional, Tanguy, Edouard, additional, Vantilcke, Vincent, additional, and Lacoste, Vincent, additional

Published
2016
Full Text
View/download PDF

27. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial

Author

Matthews, Gail, Jacoby, Simone, Borok, Margaret, Eriobu, Nnakelu, Kaplan, Richard, Kumarasamy, Nagalingeswaran, Bennet, Jaclyn Ann, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Wagner Cardoso, Sandra, Azwa, Iskander, Losso, Marcelo, Brown, Dannae, Arlinda, Dona, Hutchinson, Jolie, Kelleher, Anthony, Cisse, Mohamed, Dao, Sounkalo, Polizzotto, Mark, Emery, Sean, Law, Matthew, Papot, Emmanuelle, Karyana, Muhammad, Lupo, Sergio, Solari, Ana Melisa, Grinsztejn, Beatriz, Wolff, Marcello, Andrade-Villanueva, Jaime, Mosqueda Gómez, Juan Luis, Chow, Ting Soo, Mohapi, Lerato, Yunihastuti, Evy, Hadi, Usman, Katu, Sudirman, Subronto, Yanri Wijayanti, Lane, H. Clifford, and Perelis, Leonardo

Abstract

Randomised comparative data on efficacy and safety of second-line antiretroviral therapy (ART) after failure of non-nucleoside reverse transcriptase inhibitors (NNRTIs) across diverse geographical settings are scarce. The aim of this study was to evaluate optimal second-line ART for people with HIV.

Published
2024
Full Text
View/download PDF

28. Risk Factors for Delayed Access to Specialized Care in French Guiana

Author

Nacher, Mathieu, primary, Papot, Emmanuelle, additional, Parriault, Marie Claire, additional, Adenis, Antoine, additional, Vantilcke, Vincent, additional, Calvez, Mélanie, additional, Hanf, Matthieu, additional, Couppié, Pierre, additional, Dufour, Julie, additional, Melle, Astrid Van, additional, and Adriouch, Leila, additional

Published
2011
Full Text
View/download PDF

30. National medical specialty guidelines of HIV indicator conditions in Europe lack adequate HIV testing recommendations: a systematic guideline review.

Author

Jordans CCE, Vasylyev M, Rae C, Jakobsen ML, Vassilenko A, Dauby N, Grevsen AL, Jakobsen SF, Raahauge A, Champenois K, Papot E, Malin JJ, Boender TS, Behrens GMN, Gruell H, Neumann A, Spinner CD, Valbert F, Akinosoglou K, Kostaki EG, Nozza S, Giacomelli A, Lapadula G, Mazzitelli M, Torti C, Matulionyte R, Matulyte E, Van Welzen BJ, Hensley KS, Thompson M, Ankiersztejn-Bartczak M, Skrzat-Klapaczyńska A, Săndulescu O, Streinu-Cercel A, Streinu-Cercel A, Miron VD, Pokrovskaya A, Hachfeld A, Dorokhina A, Sukach M, Lord E, Sullivan AK, and Rokx C

Subjects
Female, Pregnancy, Humans, Europe epidemiology, Europe, Eastern, HIV Testing, HIV Infections diagnosis, HIV Infections epidemiology, Medicine
Abstract

BackgroundAdequate identification and testing of people at risk for HIV is fundamental for the HIV care continuum. A key strategy to improve timely testing is HIV indicator condition (IC) guided testing.AimTo evaluate the uptake of HIV testing recommendations in HIV IC-specific guidelines in European countries.MethodsBetween 2019 and 2021, European HIV experts reviewed guideline databases to identify all national guidelines of 62 HIV ICs. The proportion of HIV IC guidelines recommending HIV testing was reported, stratified by subgroup (HIV IC, country, eastern/western Europe, achievement of 90-90-90 goals and medical specialty).ResultsOf 30 invited European countries, 15 participated. A total of 791 HIV IC guidelines were identified: median 47 (IQR: 38-68) per country. Association with HIV was reported in 69% (545/791) of the guidelines, and 46% (366/791) recommended HIV testing, while 42% (101/242) of the AIDS-defining conditions recommended HIV testing. HIV testing recommendations were observed more frequently in guidelines in eastern (53%) than western (42%) European countries and in countries yet to achieve the 90-90-90 goals (52%) compared to those that had (38%). The medical specialties internal medicine, neurology/neurosurgery, ophthalmology, pulmonology and gynaecology/obstetrics had an HIV testing recommendation uptake below the 46% average. None of the 62 HIV ICs, countries or medical specialties had 100% accurate testing recommendation coverage in all their available HIV IC guidelines.ConclusionFewer than half the HIV IC guidelines recommended HIV testing. This signals an insufficient adoption of this recommendation in non-HIV specialty guidelines across Europe.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results